Ticagrelor is a new oral antiplatelet drug that has a strong proven benefit of reducing the rate of death from cardiovascular causes, myocardial infarction, and stroke compared with clopidogrel. Ticagrelor is widely used by patients with acute coronary syndrome. However, profound thrombocytopenia has never been previously reported in such patients. We herein present our experience with a case of profound thrombocytopenia after ticagrelor administration. No drug possibly associated with thrombocytopenia was concomitantly prescribed. The patient's platelet count recovered rapidly after ticagrelor and platelet transfusion were discontinued.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5611356 | PMC |
| http://dx.doi.org/10.6515/acs20161021c | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Influence of Coagulopathy on Radiographic and Clinical Outcomes in Patients Undergoing Middle Meningeal Artery Embolization as Standalone Treatment for Non-acute Subdural Hematomas.
J Neurotrauma
June 2024
Department of Neurosurgery, Clinical Neurosciences Center, University of Utah, Salt Lake City, Utah, USA.
Article Synopsis
- Middle meningeal artery embolization (MMAE) is being recognized as an effective treatment for non-acute subdural hematomas (NASHs), but its impact on coagulopathic patients needs further investigation.
- In a study analyzing 537 patients undergoing MMAE from 2019 to 2023, researchers found that coagulopathy significantly increases the likelihood of needing additional surgical intervention post-treatment.
- Specifically, patients with coagulopathy required rescue surgery at rates almost three times higher than those without coagulopathy, suggesting that anticoagulant and antiplatelet use may worsen outcomes.
Immune Thrombocytopenic Purpura and Intracranial Stenting.
J Pharm Pract
October 2024
Department of Pharmacy, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
Patients with immune thrombocytopenic purpura (ITP) presenting with indications for dual antiplatelet therapy (DAPT) can be difficult to manage due to the precarious balance of managing the need for increased platelet counts as well as inhibition of platelet activity. This case represents a 65 year old woman with ITP who presented with a bilateral subarachnoid hemorrhage secondary to a left ophthalmic aneurysm that required placement of a pipeline embolization device (PED) necessitating DAPT. After treatment of her ITP with pulse dexamethasone for four days, she was safely discharged on one month of DAPT with aspirin and ticagrelor then switched to aspirin monotherapy without any immediate complications.
View Article and Find Full Text PDFKey considerations in navigating ticagrelor's reported effect on heparin-induced thrombocytopenia functional assays in a landscape of limited data.
Am J Health Syst Pharm
June 2024
Department of Pharmacy Services, St. Jude Medical Center, Fullerton, CA, USA.
Purpose: This article discusses key considerations regarding ticagrelor's reported effect on heparin-induced thrombocytopenia functional assays, such as literature gaps and possible management strategies.
Summary: Limited data indicate that ticagrelor may induce false-negative results in functional assays used in the diagnosis of heparin-induced thrombocytopenia. False-negative functional assays for heparin-induced thrombocytopenia could have catastrophic consequences.
A Case Report of Ticagrelor-Induced Thrombocytopenia.
Int Med Case Rep J
July 2023
Department of Medicine, College of Medicine, King Faisal University, Al-Ahsa, Saudi Arabia.
Introduction: We report a case of new-onset thrombocytopenia following administration of a loading dose of ticagrelor.
Case Presentation: A 66-year-old male known to have diabetes mellitus type II, chronic obstructive airway disease, and hypertension presented to the emergency department with retrosternal chest pain and dyspnea. Work-up on presentation showed Hb 14.
False-Negative Functional Tests for Heparin-Induced Thrombocytopenia in Patients Receiving Ticagrelor: A Case Report.
J Clin Pharmacol
October 2023
Clinical Pharmacy Specialist, Cardiologly/Cardiothoracic Critical Care, NewYork-Presbyterian Hospital/Weill Cornell Medical Center, New York, NY, USA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!